Cytokinetics Incorporated  (CYTK)
Other Ticker:  


What are Cytokinetics Incorporated's Business Segments?

Cytokinetics Incorporated is a biopharmaceutical company focused on discovering and developing muscle-directed medicines for debilitating diseases with unmet medical needs. The company primarily focuses on developing small molecule therapeutics that improve muscle function in diseases such as heart failure, ALS, hypertrophic cardiomyopathy, and spinal muscular atrophy.


Cytokinetics Incorporated operates in a single business segment, which includes the discovery, development, and commercialization of muscle-directed medicines.


Cytokinetics is primarily focused on the development of small molecule therapeutics that enhance muscle function in various diseases. Currently, the company has the following products in their pipeline:

1. Omecamtiv Mecarbil: This drug candidate is being developed in collaboration with Amgen for the treatment of heart failure. It is a cardiac myosin activator that improves cardiac muscle function and has shown promising results in clinical trials.

2. Reldesemtiv: This drug candidate is being developed for the treatment of spinal muscular atrophy, ALS, and other neuromuscular disorders. It is a fast skeletal muscle troponin activator that increases muscle contractility and endurance.

3. CK-274: This drug candidate is being developed for the treatment of hypertrophic cardiomyopathy, a disease characterized by an enlarged heart. It is a cardiac myosin inhibitor that reduces the excessive contractility of the heart muscle.


In addition to their drug development pipeline, Cytokinetics offers a range of services to support their research and development activities. These services include:

1. Preclinical services: Cytokinetics provides a wide range of preclinical services to support drug development, including drug synthesis, pharmacology, toxicology, and formulation services.

2. Clinical trial management: Cytokinetics has extensive experience in clinical trial management, providing services such as protocol development, site management, patient recruitment, and data management.

3. Scientific consulting: Cytokinetics offers consulting services to help clients develop and optimize drug development strategies based on their expertise in muscle biology, pharmacology, and clinical trial design.

Overall, Cytokinetics Incorporated is focused on discovering and developing innovative treatments for debilitating diseases that impact muscle function. The company's pipeline of small molecule therapeutics is designed to improve muscle function in various diseases, from heart failure to neuromuscular disorders. In addition to their drug development pipeline, Cytokinetics also offers a range of services to support their research and development activities, such as preclinical services, clinical trial management, and scientific consulting.

Cytokinetics Incorporated Tax Rate Companies within the Major Pharmaceutical Preparations Industry

Business Segments Q3
(in millions $)
(in millions $)
(Sep 30 2023)
(Profit Margin)
Total 0.38 -129.42 -

Growth rates by Segment Q3
Y/Y Revenue
(Sep 30 2023)
Q/Q Revenue
Y/Y Income
(Sep 30 2023)
Q/Q Income
Total -84.97 % -56.4 % - -

To get more information on Cytokinetics Incorporated's Total segment. Select each division with the arrow.


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com